I think that it would be a very smart investment for Novartis to buy Oxford BioMedica, but I think that it would be better for Oxford BioMedica shareholders if Oxford BioMedica remained independent and was able to mature and expand its pipeline of drugs.
Remember that Oxford BioMedica has a relationship with Pfizer where Pfizer is using a license from Oxford BioMedica currently in a Phase 1 trial using the 5t4 antigen in an ADC to treat various solid cancers. I believe that this trial may already be showing exceptional progress.
https://clinicaltrials.gov/ct2/show/NCT01891669?term=Adc+5t4&rank=1
Remember also that Oxford BioMedica is working with GSK on six different gene therapies.
GlaxoSmithKline (GSK)
"...Six products granted an GSK option to a non-exclusive license under our LentiVector® platform technology patents, for the development and commercialization of up to six product candidates targeting rare orphan diseases...."
- See more at: http://www.oxfordbiomedica.co.uk/our-partners/#.dpuf
Oxford BioMedica is on the forefront of a a new medicine using gene therapy to cure diseases in the 21st century.
Good luck and GOD bless,
George
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM